Melanoma-Targeted Chemothermotherapy and In Situ Peptide Immunotherapy through HSP Production by Using Melanogenesis Substrate, NPrCAP, and Magnetite Nanoparticles
Figure 6
Hyperthermia of melanoma cells using B16OVA cells for induction of CTL in CTI therapy. Cytotoxic activity of spleen cells after CTI therapy against B16OVA cells, B16F1 cells, EL4 cells, EL4 cells pulsed with SL8 peptide (OVA-immunodominant peptide), or YAC-1 cells was determined by standard 51Cr-release assay. B16OVA cells were subjected to hyperthermia using NPrCAP/M with AMF exposure in vitro.
